Civica Rx plans to make lower cost versions of three branded insulin products, biosimilars that are expected to reach the market in 2024. In addition to $30 vials, Civica plans to sell pen cartridges at $55 for a box of five.
The partnership includes a $30 million upfront payment from Bayer and potentially more than $100 million in milestones per program generated through the partnering of the German drugmaker's molecule library and Recursion's artificial intelligence-based drug discovery platform.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
PhotoPharmics has raised $11 million and aims to raise another $10 million to help in the development and commercialization of its specialized light therapy device to treat Parkinson's Disease.
The test, designed at Rutgers University under a partnership with Spectrum Solutions and Accurate Diagnostic Labs, is designed to allow for broader population screening than the current, more prevalent method of nose and throat swabs.
Salt Lake City-based Myriad Genetics' GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression.
Recursion's technology works by generating millions of cellular images and using AI-based software as a way to analyze the data set and screen potential therapeutic compounds against a variety of diseased cells.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The idea behind the new company - dubbed Castell - is to use Intermountain's resources and learnings from its own efforts to shift to value-based care to help other providers on that journey.
Vizient, a healthcare performance improvement company, will use its analytics and data capabilities to help Civica Rx anticipate gaps in drug availability and affordability.
The 30,000-square-foot facility in Salt Lake City will be used for evaluating, testing and designing new revenue cycle management technologies for hospitals, health systems and physician groups and will also serve as a client experience center.
Last month, it was reported that IBM would stop selling Watson for Drug Discovery, but executives in the field of biopharma artificial intelligence say the field is still going strong.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The program will include services like remote monitoring, virtual urgent care visits through Intermountain Connect Care, appointment video visits and physical therapy, to name a few.
Through the round led by OrbiMed, the Salt Lake City data analytics company has become a healthcare unicorn.
The key part of the collaboration involves loading Intermountain's data into MDClone's Sandbox within the walls of Intermountain, then evaluating the data to understand crucial points in a patient's care journey.
The combined company, based in Sandy, Utah and Paris, Maine, will be focused on offering software and consulting services generally limited to large healthcare systems to providers ranging from large ACOs to independent practices.
Civica Rx, announced earlier this year, formally established with $30 million in philanthropy money, a former Amgen exec as CEO and a focus on 14 drugs facing shortages.